229 related articles for article (PubMed ID: 24532578)
1. Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.
Wu J; Shin J; Xie D; Wang H; Gao J; Zhong XP
J Immunol; 2014 Mar; 192(6):2643-50. PubMed ID: 24532578
[TBL] [Abstract][Full Text] [Related]
2. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.
Parekh VV; Lalani S; Kim S; Halder R; Azuma M; Yagita H; Kumar V; Wu L; Kaer LV
J Immunol; 2009 Mar; 182(5):2816-26. PubMed ID: 19234176
[TBL] [Abstract][Full Text] [Related]
4. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
5. β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.
O'Konek JJ; Kato S; Takao S; Izhak L; Xia Z; Illarionov P; Besra GS; Terabe M; Berzofsky JA
Clin Cancer Res; 2013 Aug; 19(16):4404-11. PubMed ID: 23804426
[TBL] [Abstract][Full Text] [Related]
6. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.
Cullen R; Germanov E; Shimaoka T; Johnston B
J Immunol; 2009 Nov; 183(9):5807-15. PubMed ID: 19812206
[TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
8. iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions.
Wu J; Yang J; Yang K; Wang H; Gorentla B; Shin J; Qiu Y; Que LG; Foster WM; Xia Z; Chi H; Zhong XP
J Clin Invest; 2014 Apr; 124(4):1685-98. PubMed ID: 24614103
[TBL] [Abstract][Full Text] [Related]
9. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.
Iyoda T; Ushida M; Kimura Y; Minamino K; Hayuka A; Yokohata S; Ehara H; Inaba K
Int Immunol; 2010 Nov; 22(11):905-13. PubMed ID: 21118907
[TBL] [Abstract][Full Text] [Related]
10. Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.
Braun NA; Mendez-Fernandez YV; Covarrubias R; Porcelli SA; Savage PB; Yagita H; Van Kaer L; Major AS
Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1758-65. PubMed ID: 20539017
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy.
Chang WS; Kim JY; Kim YJ; Kim YS; Lee JM; Azuma M; Yagita H; Kang CY
J Immunol; 2008 Nov; 181(10):6707-10. PubMed ID: 18981087
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency.
Wingender G; Krebs P; Beutler B; Kronenberg M
J Immunol; 2010 Sep; 185(5):2721-9. PubMed ID: 20660713
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1.
Kojo S; Elly C; Harada Y; Langdon WY; Kronenberg M; Liu YC
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17847-51. PubMed ID: 19815501
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor TSC1 is critical for T-cell anergy.
Xie DL; Wu J; Lou YL; Zhong XP
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14152-7. PubMed ID: 22891340
[TBL] [Abstract][Full Text] [Related]
16. Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells.
Kamata T; Suzuki A; Mise N; Ihara F; Takami M; Makita Y; Horinaka A; Harada K; Kunii N; Yoshida S; Yoshino I; Nakayama T; Motohashi S
Cancer Immunol Immunother; 2016 Dec; 65(12):1477-1489. PubMed ID: 27631416
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.
Wang Y; Bhave MS; Yagita H; Cardell SL
Front Immunol; 2020; 11():581301. PubMed ID: 33193386
[TBL] [Abstract][Full Text] [Related]
18. Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.
Choi J; Rudak PT; Lesage S; Haeryfar SMM
J Immunol; 2019 Oct; 203(7):1808-1819. PubMed ID: 31462506
[TBL] [Abstract][Full Text] [Related]
19. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.
Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
